½ÃÀ庸°í¼­
»óǰÄÚµå
1660696

Á¶Á÷ Áø´Ü ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çüº°, ±â¼úº°, Áúȯº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)

Tissue Diagnostics Market Report by Product Type, Technology, Disease, End-User, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 139 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Á¶Á÷ Áø´Ü ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 58¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â¿¡´Â 98¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 5.64%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

Á¶Á÷ Áø´ÜÀº Áúº´ÀÇ »ý¹°ÇÐÀû ¹è°æÀ» ÆÄ¾ÇÇϱâ À§ÇØ Æ¯Á¤ Á¶Á÷ »ùÇÃÀ» ºÐ¼®ÇÏ°í °Ë»çÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¾ÏÀ̳ª ¿°Áõ¼º Áúȯ°ú °°Àº ƯÁ¤ ÁúȯÀ» °¨ÁöÇÏ´Â µ¥ »ç¿ëµÇ¸ç, ¾Ç¼º Á¾¾çÀÇ Á¤È®ÇÑ Á¾·ù¿Í Á¤µµ¸¦ ÆÄ¾ÇÇÏ¿© ÀáÀçÀûÀÎ ¿øÀΰú Ä¡·á¹ýÀ» ÆÄ¾ÇÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Á¶Á÷ Áø´ÜÀº ¸Å¿ì Á¤È®Çϰí Àú·ÅÇϸç, ÄÚ¾î »ý°ËÀ̳ª °³º¹ »ý°Ë µî ´Ù¾çÇÑ ¹æ¹ýÀ¸·Î ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù¿¡´Â ¸é¿ªÁ¶Á÷È­ÇÐ(IHC), in situ hybridization(ISH), µðÁöÅÐ º´¸®ÇÐ, Ư¼ö¿°»ö µîÀÇ Ã·´Ü ±â¼úµµ Áø´Ü¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

Ãâ»êÀ² °¨¼Ò¿Í Æò±Õ ¼ö¸íÀÇ Áõ°¡·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ³ëÀÎ Àα¸ÀÇ ºñÀ²ÀÌ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ³ëÀÎÀº ¸¸¼ºÁúȯ¿¡ °É¸®±â ½±±â ¶§¹®¿¡ ÀæÀº °Ë»ç¿Í Áø´ÜÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ ¿Ü¿¡µµ ½Ä½À°üÀÇ º¯È­, ¾ËÄÚ¿Ã ¼·Ãë Áõ°¡, ½Åü Ȱµ¿ °¨¼Ò µîÀ¸·Î ÀÎÇØ ÀϺΠ»ýȰ½À°üº´ÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î ¸ðµç ¿¬·É´ë¿¡¼­ ´Ù¾çÇÑ Á¾·ùÀÇ ¾ÏÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ÀÌ·¯ÇÑ Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • Àü ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀå ±Ô¸ð´Â?
  • 2025-2033³â ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • COVID-19°¡ ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀÇ Á¦Ç° À¯Çüº° ½ÃÀå ÇöȲÀº?
  • Àü ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀÇ ±â¼úº° ½ÃÀå ÇöȲÀº?
  • Àü ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀÇ Áúȯº° ½ÃÀå ÇöȲÀº?
  • ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀÇ ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ÇöȲÀº?
  • ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä Ç÷¹À̾î/±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Á¶Á÷ Áø´Ü ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°
  • ½ÃÀå ³»¿ª : ±â¼úº°
  • ½ÃÀå ³»¿ª : Áúȯº°
  • ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°
  • ½ÃÀå ³»¿ª : Áö¿ªº°
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°

  • ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼Ò¸ðǰ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ±â¼úº°

  • ¸é¿ªÁ¶Á÷È­ÇÐ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ISH(In Situ Hybridization)
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • µðÁöÅÐ º´¸®Çаú ¿öÅ©ÇÃ·Î¿ì °ü¸®
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Ư¼ö ¿°»ö
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : Áúȯº°

  • À¯¹æ¾Ï
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • À§¾Ï
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¸²ÇÁÁ¾
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Àü¸³¼±¾Ï
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ºñ¼Ò¼¼Æ÷Æó¾Ï
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿¬±¸¼Ò
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Á¦¾àȸ»ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼öŹ¿¬±¸±â°ü
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • À¯·´
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

  • °¡°Ý ÁöÇ¥
  • °¡°Ý ±¸Á¶
  • ¸¶Áø ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Roche
    • Danaher
    • Thermo Fisher Scientific
    • Abbott
    • Agilent Technologies
    • Merck
    • Sakura Finetek Japan
    • Abcam
    • BD
    • Qiagen
    • Bio SB
    • Biogenex
    • Cell Signaling Technology
ksm 25.03.11

The global tissue diagnostics market size reached USD 5.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.8 Billion by 2033, exhibiting a growth rate (CAGR) of 5.64% during 2025-2033.

Tissue diagnostics include the analysis and testing of specific tissue samples by capturing the biological context of diseases. They are used to detect certain medical conditions like cancer and inflammatory disorders and reveal the exact type and degree of malignancy which assists in identifying potential causes and treatment options. Tissue diagnostics are highly accurate, inexpensive and can be carried out by different techniques like core and open biopsy. Nowadays, advanced technologies like immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology and special staining are also being employed for performing these diagnoses.

Owing to the declining fertility rates and increased life expectancy, the overall share of the geriatric population is currently experiencing steady growth worldwide. This is a crucial factor contributing to the market growth as older adults are more susceptible to chronic diseases and thus require frequent check-ups and diagnoses. Apart from this, altering food patterns, rising alcohol consumption and reduced physical activities among individuals have led to a rise in the incidences of several lifestyle diseases. In addition to this, the rising prevalence of various types of cancers among all age groups has also led to a surge in demand for these diagnostic services.

Key Market Segmentation:

Breakup by Product Type:

  • Instruments
  • Consumables

Breakup by Technology:

  • Immunohistochemistry
  • In Situ Hybridization
  • Digital Pathology and Workflow Management
  • Special Staining

Breakup by Disease:

  • Breast Cancer
  • Gastric Cancer
  • Lymphoma
  • Prostate Cancer
  • Non-Small Cell Lung Cancer
  • Others

Breakup by End-User:

  • Hospitals
  • Research Laboratories
  • Pharmaceutical Companies
  • Contract Research Organizations
  • Others

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Roche, Danaher, Thermo Fisher Scientific, Abbott, Agilent Technologies, Merck, Sakura Finetek Japan, Abcam, BD, Qiagen, Bio SB, Biogenex, Cell Signaling Technology, etc

Key Questions Answered in This Report

  • 1.How big is the global tissue diagnostics market?
  • 2.What is the expected growth rate of the global tissue diagnostics market during 2025-2033?
  • 3.What are the key factors driving the global tissue diagnostics market?
  • 4.What has been the impact of COVID-19 on the global tissue diagnostics market?
  • 5.What is the breakup of the global tissue diagnostics market based on the product type?
  • 6.What is the breakup of the global tissue diagnostics market based on the technology?
  • 7.What is the breakup of the global tissue diagnostics market based on the disease?
  • 8.What is the breakup of the global tissue diagnostics market based on the end-user?
  • 9.What are the key regions in the global tissue diagnostics market?
  • 10.Who are the key players/companies in the global tissue diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Tissue Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Product Type
  • 5.5 Market Breakup by Technology
  • 5.6 Market Breakup by Disease
  • 5.7 Market Breakup by End-User
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Consumables
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Immunohistochemistry
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 In Situ Hybridization
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Digital Pathology and Workflow Management
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Special Staining
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Gastric Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Lymphoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Prostate Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Non-Small Cell Lung Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Pharmaceutical Companies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Contract Research Organizations
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

  • 14.1 Price Indicators
  • 14.2 Price Structure
  • 14.3 Margin Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Roche
    • 15.3.2 Danaher
    • 15.3.3 Thermo Fisher Scientific
    • 15.3.4 Abbott
    • 15.3.5 Agilent Technologies
    • 15.3.6 Merck
    • 15.3.7 Sakura Finetek Japan
    • 15.3.8 Abcam
    • 15.3.9 BD
    • 15.3.10 Qiagen
    • 15.3.11 Bio SB
    • 15.3.12 Biogenex
    • 15.3.13 Cell Signaling Technology
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦